| ORIGINAL ARTICLE
|Year : 2020 | Volume
| Issue : 2 | Page : 160-165
Robotic-assisted surgery for colorectal liver metastasis: A single-centre experience
Simone Guadagni1, Niccolò Furbetta1, Gregorio Di Franco1, Matteo Palmeri1, Desirée Gianardi1, Matteo Bianchini1, Martina Guadagnucci1, Luca Pollina2, Gianluca Masi3, Chiara Cremolini3, Alfredo Falcone3, Franco Mosca4, Giulio Di Candio1, Luca Morelli5
1 Department of Surgery, Translational and New Technologies in Medicine, General Surgery Unit, University of Pisa, Pisa, Italy
2 Department of Surgical, Medical, Molecular Pathology and Critical Area, Division of Surgical Pathology, University of Pisa, Pisa, Italy
3 Department of Oncology, University Hospital of Pisa, Pisa, Italy
4 EndoCAS (Center for Computer Assisted Surgery), University of Pisa, Pisa, Italy
5 Department of Surgery, Translational and New Technologies in Medicine, General Surgery Unit; EndoCAS (Center for Computer Assisted Surgery), University of Pisa, Pisa, Italy
Background: Although minimally invasive surgery (MIS) of the liver is increasingly widespread, its role in the treatment of colorectal liver metastasis (CRLM) remains uncertain. In this setting, the role of robotic-assisted surgery (RAS) has not been significantly evaluated yet. The aim of this study was to report our experience with RAS for treatment of CRLM.
Material and Methods: Prospectively collected surgical and oncologic data on all of the robotic-assisted liver resections for CRLM performed at our centre were retrieved from the institutional database and retrospectively analysed. Intra-operative ultrasound (US) was obtained with a dedicated robotic probe using the TilePro™ function.
Results: Twenty patients underwent robotic-assisted resection of CRLM between May 2012 and April 2018. Six patients (30%) had multiple synchronous CRLM resections (median = 2; range 2–4). The tumour size averaged 3.0 ± 1.8 cm. All of the lesions were removed using a parenchymal-sparing approach, with R0 resection margins. Mean hospital stay was 4.7 ± 1.8 days. The mean follow-up was 22.5 ± 19.5 months. During the study period, there were no local recurrences, while 9 patients (45%) developed new systemic metastasis. All patients are still alive as of September 2018 with 1- and 3-year disease-free survival of 89.5% and 35.8%, respectively.
Conclusions: In our experience, RAS for CRLM surgical treatment was feasible and played a positive role even in patients with multiple metastases and previous or synchronous surgery. RAS seemed to be oncologically effective in this setting, as no patients experienced local relapse in the treated area.
Dr. Luca Morelli
Department of Surgery, Translational and New Technologies in Medicine, General Surgery Unit, University of Pisa, University of Pisa, Via Paradisa 2, Pisa 56125
Source of Support: None, Conflict of Interest: None
[FULL TEXT] [PDF]*